Although anti-PSMA scFv has shown promising effects for prostate cancer immunotherapy and has been introduced as a tool for building theranostic reagents for prostate cancer30, it originated from a murine monoclonal antibody which induces human anti mouse antibody response (HAMA)45,46. Here, FOLH1 is linked to prostate carcinoma.